What is a stock summary page? Click here for an overview.
Business Description
Orchestra BioMed Holdings Inc
NAICS : 541714
SIC : 2833
ISIN : US68572M1062
Description
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.04 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.5 | |||||
| Debt-to-EBITDA | -0.26 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -5.75 | |||||
| Beneish M-Score | -3.81 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -35.9 | |||||
| 3-Year EPS without NRI Growth Rate | -32.1 | |||||
| 3-Year FCF Growth Rate | -30.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -7.81 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 14.69 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.01 | |||||
| 9-Day RSI | 33.8 | |||||
| 14-Day RSI | 36.44 | |||||
| 3-1 Month Momentum % | -29.19 | |||||
| 6-1 Month Momentum % | -16.33 | |||||
| 12-1 Month Momentum % | -16.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.27 | |||||
| Quick Ratio | 4.26 | |||||
| Cash Ratio | 4.12 | |||||
| Days Inventory | 264.09 | |||||
| Days Sales Outstanding | 12.54 | |||||
| Days Payable | 8009.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 | |||||
| Shareholder Yield % | -9.09 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.27 | |||||
| Operating Margin % | -2437.49 | |||||
| Net Margin % | -2313.27 | |||||
| FCF Margin % | -1927.48 | |||||
| ROE % | -122.77 | |||||
| ROA % | -75.95 | |||||
| ROIC % | -512.06 | |||||
| 3-Year ROIIC % | -1489.21 | |||||
| ROC (Joel Greenblatt) % | -2192.33 | |||||
| ROCE % | -96.5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 43.6 | |||||
| PB Ratio | 3.57 | |||||
| Price-to-Tangible-Book | 3.57 | |||||
| EV-to-EBIT | -1.29 | |||||
| EV-to-EBITDA | -1.29 | |||||
| EV-to-Revenue | 31.41 | |||||
| EV-to-Forward-Revenue | 16.13 | |||||
| EV-to-FCF | -1.63 | |||||
| Price-to-Net-Current-Asset-Value | 4.51 | |||||
| Price-to-Net-Cash | 5.02 | |||||
| Earnings Yield (Greenblatt) % | -77.52 | |||||
| FCF Yield % | -43.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Orchestra BioMed Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.638 | ||
| EPS (TTM) ($) | -1.67 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 85.01 | ||
| 14-Day RSI | 36.44 | ||
| 14-Day ATR ($) | 0.450006 | ||
| 20-Day SMA ($) | 4.15575 | ||
| 12-1 Month Momentum % | -16.33 | ||
| 52-Week Range ($) | 3.02 - 8.8699 | ||
| Shares Outstanding (Mil) | 37.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Orchestra BioMed Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Orchestra BioMed Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Orchestra BioMed Holdings Inc Frequently Asked Questions
What is Orchestra BioMed Holdings Inc(OBIO)'s stock price today?
The current price of OBIO is $3.03. The 52 week high of OBIO is $8.87 and 52 week low is $3.02.
When is next earnings date of Orchestra BioMed Holdings Inc(OBIO)?
The next earnings date of Orchestra BioMed Holdings Inc(OBIO) is 2025-04-03 Est..
Does Orchestra BioMed Holdings Inc(OBIO) pay dividends? If so, how much?
Orchestra BioMed Holdings Inc(OBIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers